DiaMedica posts Phase 2 DM199 kidney disease results, years after trial completion
Results for the REDUX trial of DM199 in chronic kidney disease appeared on its registry record more than four years after the study finished.
DiaMedica Therapeutics had one registry update this week, a results posting for a completed kidney disease trial.
- DiaMedica's Phase 2 "REDUX" study of DM199 in chronic kidney disease, sponsored by DiaMedica Therapeutics Inc, is listed as completed, with primary completion and study completion both dated 2022-03-16.1 The trial was designed for approximately 90 participants in three cohorts,1 but actual enrollment reached 84 participants.1 Cohorts covered African Americans with CKD Stage II or III with hypertension and non-diabetic status, participants with IgA nephropathy and CKD Stage II or III, and participants with Type II diabetes, CKD Stage II or III, and hypertension,1 each tested at two doses, DM199 2.0 µg/kg or 5.0 µg/kg, given subcutaneously twice weekly for 95 days.1 Results were first posted to the registry on 2026-11-10, according to the record, more than four and a half years after the study completed in March 2022.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.